NASDAQ:RARE
Ultragenyx Pharmaceutical Inc. Stock News
$40.90
-0.320 (-0.776%)
At Close: May 10, 2024
Stock Market Crumbles; Indexes Dive, More Leaders Break; Monolithic Power, Ultragenyx Strong
04:20pm, Friday, 30'th Oct 2020
Stock market crumbles: Indexes Dive More Leaders Break; Monolithic Power, Ultragenyx strong. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists
Ultragenyx Announces Pricing of Public Offering of Common Stock
07:00pm, Wednesday, 28'th Oct 2020
NOVATO, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serio
Ultragenyx Announces Proposed Public Offering of Common Stock
07:47am, Wednesday, 28'th Oct 2020
NOVATO, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serio
Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q3 2020 Results - Earnings Call Transcript
06:16am, Wednesday, 28'th Oct 2020
Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q3 2020 Results - Earnings Call Transcript
Ultragenyx Pharmaceutical Sales More Than Triple, Pares Losses
05:01pm, Tuesday, 27'th Oct 2020
Ultragenyx Pharmaceutical posted third-quarter results late Tuesday that beat views on the top and bottom lines after RARE stock hit a nearly five-year high, revenue more than triples. The post Ultrag
Recap: Ultragenyx Pharmaceutical Q3 Earnings
04:59pm, Tuesday, 27'th Oct 2020
Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 42.35% over the past year to ($1.13
Ultragenyx Reports Third Quarter 2020 Financial Results and Corporate Update
04:05pm, Tuesday, 27'th Oct 2020
Third quarter 2020 total revenue of $ 81.5 million and Crysvita 1 revenue of $37.3 million
